Jacobio Pharmaceuticals Group (HKG:1167) said the European Medicines Agency granted the orphan drug designation to its cancer drug, according to a Monday filing with the Hong Kong bourse.
JAB-21822, KRAS G12C inhibitor Glecirasib, can be used in treating several cancers, including non-small cell lung cancer (NSCLC), pancreatic cancer, and in combination with cetuximab in colorectal cancer, the filing said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.